Other
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
Biogen Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect decreased by 64.6% to $392.2M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 107.5%, from $189M to $392.2M.
Analysis
StatementIncome Statement
SectionOther
First reportedQ1 2019
Last reportedQ1 2026Apr 29, 2026
Metric ID:
other_cash_cash_equivalents_restricted_cash_and_restrict_042e3dHistorical Data
13 periods
| Q2 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $510.1M | -$502.7M | $958.5M | $1.08B | -$541.1M | -$276.3M | -$301.2M | $47.6M | $847.1M | $189M | $92.2M | $1.11B | $392.2M |
| QoQ Change | — | -198.5% | +290.7% | +12.8% | -150.0% | +48.9% | -9.0% | +115.8% | >999% | -77.7% | -51.2% | >999% | -64.6% |
| YoY Change | — | — | +87.9% | — | -7.6% | -128.8% | -127.9% | +108.8% | +406.6% | +297.1% | -89.1% | — | +107.5% |
Range-$541.1M – $1.11B
CAGR-8.4%
Avg YoY Growth+72.7%
Median YoY Growth+87.9%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect at Other Companies
Frequently Asked Questions
- What is Biogen's cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect?
- Biogen (BIIB) reported cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect of $392.2M in Q1 2026.
- How has Biogen's cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect changed year-over-year?
- Biogen's cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect increased by 107.5% year-over-year, from $189M to $392.2M.